Search Within

Gunjan Lalitchandra Shah

Formats
  1. Meeting Abstract (291)
  2. Journal Article (132)
  3. Research Letter (15)
  4. Review (6)
  5. Correspondence (3)
  6. Guidelines (1)
Groups
  1. Bone Marrow Transplant (448)
  2. Center for Hematologic Malignancies (448)
  3. Department of Medicine (448)
  4. Hematologic Malignancies, Division of (448)
  5. Survivorship Research (448)
  6. Hematology-Oncology Fellows (347)

More Groups

People
  1. Sergio Giralt (311)
  2. Michael Scordo (299)
  3. Miguel-Angel Perales (204)
  4. Sean Devlin (187)
  5. Heather Landau (164)
  6. Parastoo Dahi (163)

More People

Years
  1. 2025 (24)
  2. 2024 (72)
  3. 2023 (85)
  4. 2022 (55)
  5. 2021 (31)
  6. 2020 (51)

More Years

Publications
  1. Blood (156)
  2. Biology of Blood and Marrow Transplantation (73)
  3. Clinical Lymphoma, Myeloma and Leukemia (39)
  4. Transplantation and Cellular Therapy (23)
  5. Blood Advances (22)
  6. Bone Marrow Transplantation (19)

More Publications

Publishers
  1. American Society of Hematology (178)
  2. Elsevier Inc. (143)
  3. Nature Publishing Group (33)
  4. American Society of Clinical Oncology (15)
  5. Taylor & Francis Group (9)
  6. Wiley Blackwell (8)

More Publishers

Results (448)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative real-world outcomes of commercial CD19-directed CAR T-cell therapies in large B-cell lymphoma
    Meeting Abstract

    Deschênes-Simard, X.; Bromberg, M.; Devlin, S. M.; Katz, O. B.; Ip, A.; Marcus, R.; Avigdor, A.; Ballweg, A.; Rabinovich, E.; Alhomoud, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Daratumumab versus lenalidomide as maintenance therapy in newly diagnosed multiple myeloma- Interim efficacy results of a randomized clinical trial
    Meeting Abstract

    Rajeeve, S.; Derkach, A.; Devlin, S. M.; Santos, J.; Przemielewska, A.; Sood, T.; Maclachlan, K. H.; Hashmi, H.; Tan, C. R.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • A Proof-of-principle of split-course bridging radiotherapy (SC-BRT) prior to CAR T-cell therapies for relapsed or refractory B-cell lymphomas: A phase 1a pilot cohort
    Meeting Abstract

    Imber, B. S.; Brosoff, A.; Roszak, E.; McAvoy, D.; Hosszu, K. K.; Boardman, A. P.; Dahi, P. B.; Shah, G. L.; Scordo, M.; Park, J. H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Investigating the novel combination of the innate cell engager (ICE®) acimtamig with off-the-shelf allogeneic natural killer cells AlloNK® in relapsed or refractory classical Hodgkin lymphoma (R/R cHL): Initial results of the phase 2 Luminice-203
    Meeting Abstract

    Maakaron, J.; Modi, D.; Mei, M. T.; Feldman, T.; Shah, G. L.; Mehta, A. N.; Sauter, C. S.; Khanal, R.; Barta, S. K.; Emig, M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • When can we define cure after CAR-T therapy in LBCL? insights from serial landmark analyses
    Meeting Abstract

    Gomez-Llobell, M.; Shouval, R.; Brown, S.; Accav, N. G.; Devlin, S. M.; Corona, M.; Rejeski, K.; Rivas-Delgado, A.; Luna, A.; Luttwak, E.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Patterns of immune reconstitution and their clinical significance in aggressive lymphoma treated with CAR-T therapy
    Meeting Abstract

    Luan, D. Y.; Dewolf, S.; Fei, T.; Raj, S. S.; Shah, G. L.; Lareau, C.; Alhomoud, M.; Salles, G.; Rivas-Delgado, A.; Rejeski, K.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Brown, S.; Devlin, S. M.; Costa, B. A.; Farzana, T.; Jurgens, E. M.; Firestone, R. S.; Nath, K.; Chung, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • CAR-tography: Longitudinal mapping of CAR-T toxicities across B-cell malignancies reveals biologically distinct and prognostically relevant toxicity phenotypes
    Meeting Abstract

    Rejeski, K.; Fei, T.; Luna, A.; Alhomoud, M.; Valtis, Y. K.; Nishimura, N.; Gomez-Llobell, M.; Accav, N. G.; Beyar-Katz, O.; Raj, S. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Barriers to immune effector cell therapy: Rapid disease progression, concern for toxicity, and lack of appropriate trials drive non-receipt after referral at a large academic center
    Meeting Abstract

    Valtis, Y. K.; Chin, K. K.; Yisraeli Salman, M.; Boussi, L.; Cadzin, B.; McLoughlin, C.; Cathcart, E.; Davis, P.; Brooklyn, C.; Goldstein, T.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Immune-MRD status informs tumor-MRD outcome prognostication in multiple myeloma patients on lenalidomide maintenance
    Meeting Abstract

    Firestone, R. S.; Simhal, A. K.; McAvoy, D.; Jurgens, E. M.; Garcés, J. J.; Nemirovsky, D.; Derkach, A.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save